NASDAQ:EPIX ESSA Pharma - EPIX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ESSA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.97 -0.08 (-2.62%) (As of 03/22/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.73▼$3.1750-Day Range$2.57▼$3.5552-Week Range$1.40▼$8.03Volume106,722 shsAverage Volume236,113 shsMarket Capitalization$130.95 millionP/E RatioN/ADividend YieldN/APrice Target$18.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media ESSA Pharma MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside522.9% Upside$18.50 Price TargetShort InterestHealthy1.26% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.84) to ($1.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.29 out of 5 starsMedical Sector944th out of 983 stocksPharmaceutical Preparations Industry460th out of 478 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $18.50, ESSA Pharma has a forecasted upside of 522.9% from its current price of $2.97.Amount of Analyst CoverageESSA Pharma has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.26% of the float of ESSA Pharma has been sold short.Short Interest Ratio / Days to CoverESSA Pharma has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ESSA Pharma has recently increased by 17.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldESSA Pharma does not currently pay a dividend.Dividend GrowthESSA Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EPIX. Previous Next 0.6 News and Social Media Coverage Search Interest8 people have searched for EPIX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ESSA Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders12.00% of the stock of ESSA Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ESSA Pharma are expected to decrease in the coming year, from ($0.84) to ($1.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ESSA Pharma is -4.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ESSA Pharma is -4.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioESSA Pharma has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ESSA Pharma (NASDAQ:EPIX) StockESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. The company develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. It has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Read More Receive EPIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address EPIX Stock News HeadlinesMarch 8, 2023 | finance.yahoo.comESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare ConferenceMarch 7, 2023 | finance.yahoo.comESSA Pharma Inc.'s (NASDAQ:EPIX) recent 12% pullback adds to one-year year losses, institutional owners may take drastic measuresMarch 22, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. February 23, 2023 | finance.yahoo.comEPIX: Deep and Sustained PSA Responses in Phase 1/2 Combination Trial of EPI-7386 and Enzalutamide…February 7, 2023 | finance.yahoo.comESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022February 2, 2023 | finance.yahoo.comESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology ConferenceJanuary 25, 2023 | finance.yahoo.comA Look At The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)December 15, 2022 | finance.yahoo.comWe're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn RateMarch 22, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. December 13, 2022 | msn.comESSA Pharma GAAP EPS of -$0.14December 13, 2022 | finance.yahoo.comESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022November 15, 2022 | finance.yahoo.comEPIX: Promising Early Data for EPI-7386 in Combination with Enzalutamide…November 10, 2022 | finance.yahoo.comESSA Pharma to Participate in Two Upcoming Investor ConferencesOctober 31, 2022 | finance.yahoo.comJ&J suspends enrollment in clinical trial assessing Essa Pharma's prostate cancer treatmentOctober 31, 2022 | finance.yahoo.comESSA Pharma Shares Tank As Janssen Stops Enrollment In EPI-7386 Combo Prostate Cancer TrialsOctober 26, 2022 | barrons.com(PR) ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR SymposiumOctober 26, 2022 | finance.yahoo.comUpdated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific RetreatSeptember 21, 2022 | finance.yahoo.comESSA Pharma Appoints Philip Kantoff to its Board of DirectorsSeptember 6, 2022 | reuters.comESSA Pharma IncAugust 25, 2022 | seekingalpha.comESSA Pharma Inc.: Selling For Under Cash ValueAugust 16, 2022 | benzinga.comMultiple Ongoing Studies of EPI-7386August 4, 2022 | finance.yahoo.comESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2022July 21, 2022 | nasdaq.comEPIX Stock Gains 11.6% on Insider BuysJuly 11, 2022 | finance.yahoo.comEPIX: Encouraging Signs of Activity in Phase 1 Trial of EPI-7386…June 30, 2022 | finance.yahoo.comESSA Pharma Insiders Establish Automatic Securities Disposition PlansJune 27, 2022 | finance.yahoo.comESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical DevelopmentJune 2, 2022 | finance.yahoo.comESSA Pharma to Present at 2022 Jefferies Healthcare ConferenceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EPIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address EPIX Company Calendar Last Earnings2/07/2023Today3/22/2023Next Earnings (Estimated)5/09/2023Fiscal Year End9/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EPIX CUSIPN/A CIK1633932 Webwww.essapharma.com Phone778-331-0962Fax604-738-4080Employees25Year FoundedN/APrice Target and Rating Average Stock Price Forecast$18.50 High Stock Price Forecast$20.00 Low Stock Price Forecast$17.00 Forecasted Upside/Downside+514.6%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,100,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-19.28% Return on Assets-18.91% Debt Debt-to-Equity RatioN/A Current Ratio56.08 Quick Ratio56.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.79 per share Price / Book0.79Miscellaneous Outstanding Shares44,090,000Free Float38,801,000Market Cap$132.71 million OptionableNot Optionable Beta2.10 Key ExecutivesDr. David Ross Parkinson M.D. (Age 73)Pres, CEO & Director Comp: $829.56kMr. David S. Wood C.M.A. (Age 66)CPA, M.B.A., MBA, CPA, CMA, Chief Financial Officer Comp: $532.35kMr. Peter A. Virsik M.B.A. (Age 52)M.S., Exec. VP & COO Comp: $646.75kDr. Alessandra Cesano M.D. (Age 63)Ph.D., Chief Medical Officer Comp: $620.81kChandtip ChandhasinExec.Erica OsbourneExec.Erin RudsinskiExec.Loleta HarrisExec.Neil ThaparExec.Nkengyal BarberExec.More ExecutivesKey CompetitorsSesen BioNASDAQ:SESNGossamer BioNASDAQ:GOSSAnixa BiosciencesNASDAQ:ANIXAnnovis BioNYSE:ANVSAkebia TherapeuticsNASDAQ:AKBAView All CompetitorsInsiders & InstitutionsSoleus Capital Management L.P.Bought 1,228,853 shares on 2/15/2023Ownership: 8.776%Morgan StanleySold 99,542 shares on 2/15/2023Ownership: 4.551%Avidity Partners Management LPSold 604,600 shares on 2/15/2023Ownership: 4.208%Millennium Management LLCSold 232,286 shares on 2/15/2023Ownership: 0.396%Susquehanna International Group LLPBought 44,100 shares on 2/14/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions EPIX Stock - Frequently Asked Questions What is ESSA Pharma's stock price forecast for 2023? 0 analysts have issued twelve-month price targets for ESSA Pharma's shares. Their EPIX share price forecasts range from $17.00 to $20.00. On average, they anticipate the company's stock price to reach $18.50 in the next year. This suggests a possible upside of 514.6% from the stock's current price. View analysts price targets for EPIX or view top-rated stocks among Wall Street analysts. How have EPIX shares performed in 2023? ESSA Pharma's stock was trading at $2.52 at the beginning of the year. Since then, EPIX stock has increased by 19.4% and is now trading at $3.01. View the best growth stocks for 2023 here. Are investors shorting ESSA Pharma? ESSA Pharma saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 236,800 shares, an increase of 17.0% from the February 13th total of 202,400 shares. Based on an average daily volume of 240,400 shares, the days-to-cover ratio is currently 1.0 days. Currently, 1.3% of the shares of the stock are sold short. View ESSA Pharma's Short Interest. When is ESSA Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. View our EPIX earnings forecast. How were ESSA Pharma's earnings last quarter? ESSA Pharma Inc. (NASDAQ:EPIX) released its earnings results on Tuesday, February, 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.09. What other stocks do shareholders of ESSA Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include RedHill Biopharma (RDHL), Aurinia Pharmaceuticals (AUPH), Lipocine (LPCN), Trevena (TRVN), Allena Pharmaceuticals (ALNA), Protalix BioTherapeutics (PLX), Agile Therapeutics (AGRX), Biopharmx (BPMX), Corbus Pharmaceuticals (CRBP) and Heat Biologics (HTBX). What is ESSA Pharma's stock symbol? ESSA Pharma trades on the NASDAQ under the ticker symbol "EPIX." Who are ESSA Pharma's major shareholders? ESSA Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Soleus Capital Management L.P. (8.78%), Morgan Stanley (4.55%), Avidity Partners Management LP (4.21%), Frazier Life Sciences Management L.P. (1.37%), Driehaus Capital Management LLC (0.60%) and Millennium Management LLC (0.40%). Insiders that own company stock include David Ross Parkinson, Franklin M Berger and Growth N V Biotech. View institutional ownership trends. How do I buy shares of ESSA Pharma? Shares of EPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ESSA Pharma's stock price today? One share of EPIX stock can currently be purchased for approximately $3.01. How much money does ESSA Pharma make? ESSA Pharma (NASDAQ:EPIX) has a market capitalization of $132.71 million. The company earns $-35,100,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. How can I contact ESSA Pharma? ESSA Pharma's mailing address is 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5. The official website for the company is www.essapharma.com. The company can be reached via phone at 778-331-0962, via email at alada@troutgroup.com, or via fax at 604-738-4080. This page (NASDAQ:EPIX) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.